

RealRate

PHARMACEUTICAL 2019

Vanda Pharmaceuticals Inc. Rank 36 of 363









PHARMACEUTICAL 2019



Vanda Pharmaceuticals Inc. Rank 36 of 363



The relative strengths and weaknesses of Vanda Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Vanda Pharmaceuticals Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 101% points. The greatest weakness of Vanda Pharmaceuticals Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 12% points.

The company's Economic Capital Ratio, given in the ranking table, is 257%, being 220% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	299,132
Cost of Goods Sold	0
Intangible Assets	24,542
Liabilities, Current	53,015
Liabilities, Non-Current	3,693
Other Assets	4,039
Other Compr. Net Income	35
Other Expenses	22,173
Other Liabilities	0
Other Net Income	0
Other Revenues	196,726
Property and Equipment	4,417
Research and Development	43,594
Selling, General and Administrative Expense	105,751

Output Variable	Value in 1000 USD
Assets	332,130
Liabilities	56,708
Expenses	171,518
Revenues	196,726
Stockholders Equity	275,422
Net Income	25,208
Comprehensive Net Income	25,226
Economic Capital Ratio	257%

